This additional iBio patent claims a system for expressing multiple polynucleotides of interest in a plant cell or whole plant using viral vectors that complement each other's viral functions in the plants. The polynucleotides can encode chains of a multimeric protein, or can encode therapeutically active proteins. The patent also describes methods for using the vector system to produce the desired proteins in plants. Additional iBioLaunch vectors are described in iBio's earlier US patent 7,491,509 issued in 2009.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.
|SOURCE iBio, Inc.|
Copyright©2010 PR Newswire.
All rights reserved